OncLive SOSS

Data Updates in GI Cancers and HCC from ESMO 2024 - Episode 4

Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

October 28, 2024

Sakti Chakrabarti, MD, Mohammed Najeeb Al Hallak, MD, MS

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on final overall survival data from the KEYNOTE-811 trial.

EP. 1: 5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC

EP. 2: The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC

EP. 3: Neoadjuvant Nivolumab Plus Ipilimumab in dMMR Colon Cancer: The NICHE-2 Trial

EP. 4: Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

EP. 5: Findings from the DESTINY-Gastric03 Trial in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

EP. 6: Building Upon Approved Combination Regimens in Unresectable HCC

EP. 7: Ongoing Research in GI Cancers